HAVCR2 and myeloid sarcoma: We evaluated LPX-TI641 in vitro and in vivo, assessing its ability to expand CD4+Foxp3+ regulatory T cells (Tregs), restore Tim-3+ Tregs in peripheral blood mononuclear cells (PBMCs) from people with MS (PwMS), and improve suppressive Treg function.